title: Case Study: Weight loss in a patient with type 2 diabetes: Challenges of diabetes management.
abstract: This patient with BMI 36 kg/m² and T2DM on insulin glargine and glyburide as well as atenolol for HTN was able to lose 10% of his initial body weight with a low-carbohydrate diet and exercise and adjustment of medications in approximately a 36-week time frame. Insulin glargine and glyburide were reduced gradually with blood glucose monitoring and replaced by an increase in metformin, start of liraglutide, and eventually phentermine/topiramate and canagliflozin (Figure). Therefore, medications that can exacerbate weight gain were discontinued in place of medications which promote weight loss.
authors.affiliation: Center for Nutrition and Weight Management, Boston Medical Center, Boston, Massachusetts, USA.
authors.forename: Katayoun
authors.initials: K
authors.lastname: Lotfi
authors.forename: Kenya
authors.initials: K
authors.lastname: Palmer
authors.forename: Caroline M
authors.initials: CM
authors.lastname: Apovian
mesh_terms: D019440:Anti-Obesity Agents / Q000008:administration & dosage*; D001835:Body Weight; D003131:Combined Modality Therapy; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy / Q000628:therapy*; D050528:Diet, Carbohydrate-Restricted; D004305:Dose-Response Relationship, Drug; D015444:Exercise; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000150:complications / Q000178:diet therapy / Q000188:drug therapy / Q000628:therapy*; D016896:Treatment Outcome; D015431:Weight Loss
chemical_list: D019440:Anti-Obesity Agents; D007004:Hypoglycemic Agents